The rising interest in successful weight management has led to considerable investigation into novel treatments. Lately , Retatrutide, a dual -action GIP and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated encouraging results in patient trials, suggesting potential for significant weight decrease. Consequently , numerous individ